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Abstract
Purpose: To verify the accuracy of volumetric arc therapy (VMAT) using the RapidArc™ device when switching
patients from one single linear accelerator (linac) to a paired energy and mechanics "twin" linac without
reoptimization of the original treatment plan.
Patients and Methods: Four centers using 8 linacs were involved in this study. Seventy-four patients previously
treated with the 6MV photon RapidArc™ technique were selected for analysis, using 242 measurements. In each
institution, all patients were planned on linac A, and their plans were verified both on linac A and on the twin linac
B. Verifications were done using the amorphous silicium electronic portal imager (EPID) of the linacs and were
analyzed with the EpiQa software (Epidos, Bratislavia, Slovakia). The gamma index formalism was used for validation
with a double threshold of 3 % and 3 mm with a measurement resolution of 0.39 mm/pixel, and a smoothed
resolution of approximately 2.5 mm.
Results: The number of points passing the gamma criteria between the measured and computed doses was
94.79 ± 2.57 % for linac A and 94.61 ± 2.46 % for linac B. Concerning the smoothed measurement analysis,
98.67 ± 1.26 % and 98.59 ± 1.20 % points passing the threshold were obtained for linacs A and B, respectively.
The difference between the 2 dose matrices acquired on the EPID was very small, with 99.92 ± 0.06 % of the
points passing the criteria.
Conclusion: For linacs sharing the same mechanical and energy parameters, this study tends to indicate that patients
may be safely switched from treatment with one linac to treatment with its twin linac using the same VMAT plan.
Background
New radiotherapy techniques aiming at improving target
coverage and protection of organs-at-risk have emerged
in the last decade. Intensity-modulated radiation therapy
(IMRT) improved dosimetric results compared with
3-dimensional conformal radiotherapy (3D-CRT) by
modulating the beam intensity for static gantry angles
[1–4]. After a development phase followed by a validation
process [5, 6], IMRT is now routinely implemented and
available for a growing number of patients. New quality
assurance procedures had to be designed for IMRT as the
complexity of optimization algorithm and technical
delivery were increasing. Software tools were developed
for quality assurance [7–9] and for treatment planning
systems [10, 11]. Guidelines on the technical and clinical
aspects of the validation of IMRT treatments were also
established [4, 12–15].
Volumetric arc therapy (VMAT), commercialized under
the names RapidArc (Varian) or VMAT (Elekta), is a re-
finement of standard IMRT which uses beam modulation
combined with a continuous or discrete arc motion of the
linac gantry around the patient. The resulting treatment
plan is often more complex than that of the standard
IMRT, which raises the question of the feasibility of
switching a patient treated with a VMAT plan computed
for a specific linac to a “twin” linac e.g. in case of repair or
maintenance. While it has been shown possible for 3D-
CRT and standard IMRT, no data is available regarding
this possibility with VMAT. We thus conducted a study in
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order to compare the accuracy of the actual patients’
VMAT plans optimized for a specific linac to the same
plans when radiotherapy is delivered on a “twin” linac.
Patients and methods
IMRT was implemented in four centers between 2001
and 2008, and more than 10 000 patients were treated
using this technique since. Data was collected on the
eight linacs (21 EX and 21 iX, Varian Medical System,
Palo Alto, CA) used to deliver IMRT treatments in
these centers. They were all equipped with 120 leaves
multi-leaf collimators (MLC) adjusted and verified by
the medical physicists so as to be equivalent regarding the
“sliding-window” delivery technique. Between 2008 and
2010, RapidArc options were installed on the linacs and
patients started to be treated with this modality. Otto
et al. [16] showed that the RapidArc combines dose-rate
modulation, gantry-speed modification and leaf position
to create a high-dose modulation during a single or few
rotations around the patient. Commissioning of the 8
linacs was carried out following the manufacturer’s sug-
gestions [17]. Given the higher number of parameters to
verify for the RapidArc technology compared to the static
gantry technique, it was important to know if the patients
could be switched from a linac for which the treatment
plan had been specifically optimized for a “twin” linac. All
linacs were equipped with amorphous silicon aS1000
(Varian) electronic portal imaging devices (EPIDs), which
allow portal-imaging dosimetry for IMRT verification [18].
In this study, we used EPIDs to validate the linac matching
and to investigate the possibility of switching a patient
from one linac to another without the need of re-
optimizing a new VMAT plan. At the time of the study,
the V8 version of ARIA did not allow the RapidArc
portal-dose predictions for comparisons with the image
measured on the AS1000. We then decided to use the
EpiQa software (Epidos, Bratislavia, Slovakia) for data
analysis, based on previous publications [19, 20].
Patients’ selection and study design
Seventy-four patients previously treated with RapidArc for
prostate (n = 10), head and neck (n = 30), pelvis (n = 20) or
miscellaneous (n = 14) cancers in four French oncology
centers (Institut régional du Cancer de Montpellier - ICM,
Montpellier, Institut de Cancérologie de la Loire, Saint
Etienne, and the ORLAM radiotherapy centers of Mâcon
and Villeurbanne) were included in the study between
2008 and 2010, and accounted for 242 measurements.
Consecutive patients were selected in each center,
independently of the quality assurance results of their pre-
treatment plan. Three centers each provided data for 10
prostate or pelvis cases plus for 10 head and neck cancer
patients, whereas the fourth center provided the 14
miscellaneous cancer cases. The dosimetric plans were
computed using Eclipse treatment planning system for a
specific linac (linac A). All the patients’ plans were then
verified through a quality assurance process on linacs A
and B, the latter having been adjusted by the physics team
to be similar during initial commissioning (see “Machine
matching”). Rotational treatment plans optimized for linac
A were delivered using linac A and linac B on a Silicium
detector attached to the gantry. The EPID measured the
collapsed plan dose in a 2-dimensional matrix, which was
then compared to the one computed in Eclipse on a
computer model of the phantom [19, 20]. The gamma
index formalism [21] was used for validation with a
threshold of 3 % and/or 3 mm, and the number of points
reaching these criteria was recorded for comparison. The
region of interest corresponded to the entire field with a
1 cm margin. A global gamma comparison method was
chosen. Since the anisotropic analytical algorithm calcula-
tion grid was 2.5 mm and the measurement resolution
was 0.39 mm/pixel, we adopted a smoothing analysis. A
Gaussian curve was applied to the measurements in order
to decrease the spatial resolution of the matrix to the one
computed in Eclipse, resulting in an acquisition matrix of
approximately 2.5 mm/pixel. A large range of photon
energies (6, 8, 18 and 25 MV) and maximum dose rates
(400 to 600 MU/min) were used to analyze if there was
specific energy or dose rate dependence of the measure-
ments. A comparison between the dose prediction and
dose calculation for linacs A and B was carried out. The
results of the plans irradiated with linacs A and B were
then compared.
Treatment planning
Optimization and calculations were done at center one
(20 patients) using the 8.0.5 version (PRO I) of the
Eclipse treatment planning system (Varian, Palo Alto,
USA), which only allowed a single arc. Results for the 10
prostate and the 10 head and neck cases were obtained
in late 2008 and early 2009. The three other centers
(2 to 4) used the 8.2.23 version of the Eclipse system,
which includes the second version of the progressive reso-
lution optimizer (PRO II) and allows an optimization for
one or two arcs. Prostate treatments were administered
with one arc whereas two arcs were used for other
pathologies.
RapidArc optimization was performed using the new
PRO algorithm that allows iterative changes to the
dynamic delivery variables (i.e. MLC, dose rate and gan-
try angular velocity) via a set of penalty functions. These
iterations were separated into five resolution levels. The
first represented the full arc with 10 control points
(mostly static fields). This number of control points was
then doubled plus one for each successive resolution
level, with the final arc including up to 177 control
points. As each new control point was added, the
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dynamic variables were interpolated from the two neigh-
boring points. The nature of this process meant that the
lower resolution levels were flexible to optimization
objective changes but gave a coarse representation of the
full arc, while the higher levels were less flexible but
gave a much more accurate representation of the full
dynamic arc.
Due to the increased time needed for optimization
using PRO I and PRO II, we adopted a strategy where
the set of constraints for a specific patient was searched
with the dose volume optimizer (DVO). The algorithm,
also used for sliding-window IMRT, is based on fluence
determination and any change in the constraints has a
direct impact on the dose-volume histograms during the
optimization. After a few iterations with the DVO, a per-
sonalized set of constraints for the specific patients was ob-
tained, which was used to facilitate RapidArc optimization.
As opposed to the DVO algorithm, machine parameters
were directly used during optimization with the PRO algo-
rithm. This could have an impact on the final results. In-
deed, the DVO algorithm generates a theoretical fluence
map at the end of its optimization process, which is con-
verted in an actual fluence by a sequencer including both
mechanical and dosimetric linac parameters. The actual
dose distribution was then computed on patient data
using the predicted fluence and this often resulted in dif-
ferences between the dose-volume histograms shown at
the end of the optimization process and those obtained
after the sequencer generated the fluence. With the PRO
algorithm, the dose-volume histogram results at the end
of the optimization process are usually very close to those
obtained after dose calculation. Dose calculation on
Eclipse used the anisotropic analytical algorithm with a
calculation grid of 2.5 mm.
Machine matching
Many parameters were checked to consider that two
linacs are matched together or form a “twin”-pair. The
first concerns relative dosimetric data. Depth dose
curves were identical (we applied a threshold of 0.5 %)
and special attention was given to small fields, especially
when the linacs were used for IMRT treatments. The dose
profiles were also checked to be as similar as possible, and
a focus on larger fields was necessary since tuning the
beam to obtain identical profiles was more difficult for
large fields. Dosimetric parameters were primordial
factors for the matching procedure. Machine calibration
was done in the same conditions and output factors did
not differ by more than 0.5 %. After these goals were
achieved and beam matching was obtained for 3D-CRT,
matching for IMRT also needed a fine MLC tuning and
leaf calibration to obtain equivalent results for both linacs.
Sharing the same MLC leakage transmission, the calibra-
tion of the dosimetric leave gaps was mechanically ad-
justed to obtain less than 0.5 % difference for the same
plan delivered on two different linacs. This method has
Fig. 1 Comparison tests for MLC and EPID calibrations. a Comparison of sliding window tests for verification of the dosimetric leave separation;
(b) picket-fence tests for leave positioning accuracy. The profiles were taken perpendicularly following the cross-hair axes display
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previously been described in the literature [4, 22, 23].
Furthermore, leaf transmission and dosimetric leave gaps
parameters were adjusted in the treatment planning
system to obtain similar measurements for the same
treatment plan, as described by Chauvet et al. [24].
Machine tests and patient quality assurance
Delivery measurements were acquired with the EPID of
the linacs using amorphous silicium (AS1000) and analysed
with the EpiQa software (Epidos, Bratislavia, Slovakia).
This program allows the conversion of a dosimetric image
acquired by an EPID into a dose map and to compare the
dose map with a reference dose distribution. It is possible
to use Epiqa for the verification of static and intensity
modulated fields.
The portal dosimetry image conversion to dose map
was based on the GLAaS algorithm as described by
Nicolini et al. [19].
Technical quality assurance for linacs A and B was
accomplished using the DICOM files provided by Varian
and following the process defined by Ling et al. [17].
The accuracy of the leave movements was tested using
the “sliding-window” and “picket fence” tests on differ-
ent gantry positions [22, 23, 25]. The results obtained
with linacs A and B were used to evaluate the quality of
the matching (Fig. 1). These tests provided a more quali-
tative than quantitative analysis, and were similar to the
Fig. 2 Global comparison of the predicted and effective dose distribution for the twin linacs with (a) and without (b) smoothing
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film dosimetry quality assurance, which has been used
for many years. A garden fence methodology was
followed to check the quality of these results [22].
Specific tests were done using the RapidArc to verify the
dose-rate, the gantry speed and the leaf speed variations
during rotation as to be assured of the consistency of
the two linacs.
Regarding the treatment plans, once the dosimetry
was finished, a quality control plan was realized using
the GlAas algorithm formalism [19], commercially avail-
able in the Epiqa software (Epidos, Bratislava, Slovakia).
A dose distribution on a virtual water phantom at the
depth of the maximum of the depth dose curve and a
distance of 100 cm to the source was calculated in
Eclipse. This verification plan, using the original parame-
ters (MLC and dose rate) was “collapsed” on an infini-
tesimal gantry rotation, generating a dose distribution of
the whole arc on a single plane, perpendicular to the
beam central axis. This dose distribution, calculated with
a resolution of 2.5 mm/pixel, was exported and
compared with the data acquired on the EPID (AS1000,
Varian Medical System, Palo Alto, CA, USA) during the
delivery of the real patients’ plan using the Epiqa
software. The GlAas algorithm was configured to con-
vert the images acquired without any build-up on the
EPID cassette into a dose at the depth of the maximum
of the depth dose curve (e.g. 1.4 cm for X6). The meas-
urement consisted of an acquisition of the real treatment
plan during the RapidArc delivery using the integrated
mode of the EPID. The detector was positioned at the
isocenter distance without any patient, phantom or
couch inside the beam. [20] Spatial resolution was an
important factor for the evaluation of the results. As the
detector provided a resolution of 0.39 mm/pixel, lower
than the 2.5 mm/pixel grid calculation in Eclipse, we
performed a second analysis using a Gaussian smoothing
method of 2 mm provided by the Epiqa software, in
order to have a comparison with similar spatial reso-
lution. Our tolerance level for acceptance of a treatment
plan was a 3 %-3 mm gamma index threshold with an
acceptance value of 95 % of the point passing these
criteria. For cases below the 95 % acceptance level, quali-
tative analysis could still lead to a quality assurance
validation. Using this data, we first compared linacs A
and B of each center calculating the difference between
dose-calculation and dose-measurement for the same
Fig. 3 Comparison of the predicted and effective dose distribution for the twin linacs by center. The X- and Y-axes represent the gamma index
result for a 3 %-3 mm analysis for linacs A and B, respectively, for a) center 1, b) center 2, c) center 3 and d) center 4
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treatment plan. Second, we compared the treatment
delivery using the measurements made with linac A
to those made with linac B. This evaluation excluded
all treatment planning system algorithm configura-
tions and was purely an indicator of the linac beam,
MLC and EPID parameters calibrations.
Results
Analysis of the “sliding window” and the “picket fence”
tests were made qualitatively by looking at the curve
correspondence on portal measurements. It showed a
good agreement between linacs A and B (Fig. 1). We took
a series of mechanical and imaging tests of the MLC using
the same DICOM file on the twin linacs, showing
equivalent results. First, the sliding window IMRT files
were used to measure absolute dose with an ionisation
chamber in a PMMA phantom to ensure proper calibra-
tion of the leaves on each MLC. Results were within 1%.
We then performed portal IMRT tests (e.g. chair, step
wedges or pyramid) and the difference for a gamma 3 %-
3 mm between the 2 linacs was less than 1 %. The specific
RapidArc quality assurance test results were concordant
with those described by Jorgensen et al. [26].
Concerning the patients treatment plans, the comparison
between measured and computed dose showed 94.79 ±
2.57 % of points passing the gamma criteria for linac A and
94.61 ± 2.46 % for linac B (Fig. 2a). For the smooth analysis,
we reached 98.67 ± 1.26 % and 98.59 ± 1.20 % for linacs A
Fig. 4 Over-modulation on measurement before smoothing. Profiles were taken perpendicularly following the cross-hair axes display
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and B, respectively (Fig. 2b). Regarding the ten head and
neck patients, the results were 94.03 ± 2.08 % and 94.20 ±
2.10 % with a measurement grid of 0.39 mm for linacs A
and B, respectively. Once again, a smoothed analysis im-
proved the results: 98.51 ± 1.39 % (A) and 98.59 ± 1.12 %
(B) of points passing a gamma ≤1 for 3 % or 3 mm.
For the prostate cancer patients, for whom the modu-
lation was much simpler, the results were 99.00 ± 0.48 %
for linac A, and 97.98 ± 0.59 % for linac B without
smoothing even for the plans optimized using the PRO
version (center 1). The results using the smoothing
method were 99.77 ± 0.31 % and 99.84 ± 0.16 % for the
linacs A and B, respectively. For patients with pelvic
cancer, results were 94.13 ± 2.44 % and 98.26 ± 1.19 %
for linac A, and 93.99 ± 231 % and 98.12 ± 1.23 % for
linac B, before and after smoothing, respectively. For
centers 2, 3 and 4, the quality assurance results on linac
A compared to those on linac B were good with a max-
imum difference of 1.9 % in the values obtained (Fig. 3b,
c, and d). For center 1, the maximal difference was 6.4 %
for a head and neck treatment delivered with a single
arc. This difference can be explained by the specificity of
verification using collapsed plans on 2D views and
because of an over modulation measured by the portal
imager (peaks on the blue line on Fig. 4), especially for
this complex case with a high modulation level. Adding
a second arc decreased the modulation level by arc, and
consequently allowed an improved result.
All plans but one passed the criteria of 3 % - 3 mm for
95 % of the points analyzed with the smooth evaluation
for the twin machines in the four institutes (Fig. 2b).
Regarding the dose distribution comparison test for
the same treatment plans acquired on different portal
devices, the differences between linacs A and B were
very small, 99.92 ± 0.06 % of points passing the criteria
(Fig. 5a). In this analysis, raw data with a 0.39 mm/pixel
resolution was used. This test is the most robust to com-
pare two matched linacs and showed excellent results
for all the participating centers (Fig. 5b).
Discussion
IMRT has the ability to deliver highly conformal dose
distributions to complex targets. In both static and rota-
tional IMRT, many parameters such as the leaf position,
dose rate and gantry speed have to be accurately
controlled by the treatment planning system in order to
achieve such coverage. Consequently, IMRT quality
assurance procedures have to be specifically developed,
using ionisation chambers, films or a 2D array [12, 27].
Although VMAT represents an evolution of IMRT, the
quality assurance process remains similar. Films and 2D
arrays are mostly used to compare the predicted and
measured doses, with results reaching the acceptation
criteria usually admitted [28–31]. More recently, the
use of EPIDs has made the quality assurance easier to
set up by taking out the need to use phantoms [32]. This
methodology, concerning IMRT quality assurance, was
adopted by many institutions [20, 32–35] Validation of
RapidArc treatments with EPIDs on 3 different matched
beam using Varian linacs was previously described by
Fredh et al. [36]. The effect of the gantry movement was
not found to significantly affect the results leading to the
use of EPIDs as a detector even in the rotational mode.
The results were quite similar even after segmenting
the 360° arc into multiple sub-arcs of 6° and 12° to
“collapse” the irradiation into a 2D measurement [20].
The consistency and reproducibility of VMAT plan
delivery were shown with 3 different quality assurance
systems by Chandraraj et al. [37].
Our study focused on the capacity of twin linacs to
deliver the same dose distribution from the same VMAT
Fig. 5 Comparison of the dose measurements between the twin
machines: global (a) and per center (b) results. Each dot on a ray
represents a value for patient measurement. The percentages of
points passing a gamma index of 3 %-3 mm are represented by the
different circle levels
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plan. The algorithm version of the optimiser was not in-
cluded in this comparison; only dosimetric and mechanical
tunings of the linacs were compared. Our results showed
good and equivalent results for all the centers, allowing the
possibility for a patient to be switched from one linac to
another without the need of repositioning a new plan,
provided that the beams and MLC are perfectly matched.
The percentage of points passing the gamma criteria
of 3 %-3 mm were similar to other studies using EPID
or films for quality assurance [38, 39], even if another
study has reported better results [40]. The value of the
gamma index highly depends on the spatial resolution
used for the analysis. Most of the publications showing
overall gamma values better than 99 % have used 2D
matrixes with a spatial resolution ranging from 5 to
10 mm, whereas EPIDs have a sub-millimeter resolution
of 0.39 mm/pixel. We performed a smoothed analysis to
render the resolution closer to a calculated planar dose.
Doing so, the results of the gamma index were signifi-
cantly improved. Another method could have been to
increase the spatial resolution of the calculation grid in
Eclipse to the lowest value proposed of 1 mm, but the
commercial hardware actually available could not carry
out this calculation on a real patient volume.
Conclusion
This study carried out on 8 linacs in 4 centers and for
different cancer types tends to indicate that it is possible
to treat a patient with the same VMAT plan on twin
linacs, provided that the linacs are perfectly matched.
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